Patents by Inventor Kengo Sonoda

Kengo Sonoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
    Patent number: 10655110
    Abstract: A highly safe dengue vaccine was invented that induced a neutralizing antibody response against all of the four serotypes of dengue virus without developing more than a fixed level of viremia with single administration. A tetravalent dengue virus formulation is provided that is excellent in both efficacy (neutralizing antibody response) and safety (viremia).
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: May 19, 2020
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Kengo Sonoda, Yasuhiko Shinmura, Susumu Yamaori, Motoharu Abe, Shinichi Maruno, Shota Takagi, Yasuhisa Hayashi, Kazuhisa Kameyama, Fusae Komura, Aki Fukuda, Naomi Uchida, Masaya Yoshimura
  • LIVE VIRUS HAVING A BANK OF DENGUE VIRUS ATTENUATED STRAINS, AND A DENGUE VACCINE CONTAINING SAME AS ANTIGENS
    Publication number: 20180340155
    Abstract: A highly safe dengue vaccine was invented that induced a neutralizing antibody response against all of the four serotypes of dengue virus without developing more than a fixed level of viremia with single administration. A tetravalent dengue virus formulation is provided that is excellent in both efficacy (neutralizing antibody response) and safety (viremia).
    Type: Application
    Filed: November 25, 2016
    Publication date: November 29, 2018
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Kengo SONODA, Yasuhiko SHINMURA, Susumu YAMAORI, Motoharu ABE, Shinichi MARUNO, Shota TAKAGI, Yasuhisa HAYASHI, Kazuhisa KAMEYAMA, Fusae KOMURA, Aki FUKUDA, Naomi UCHIDA, Masaya YOSHIMURA
  • Recombinant Marek's disease virus (MDV) and vaccine
    Patent number: 6013261
    Abstract: A recombinant herpes virus is provided which efficiently expresses an exogenous protein of interest in an inoculated animal host to thereby endow the host with excellent immunization. A recombinant herpes virus which incorporates an exogenous gene expression cassette in which a herpes virus-derived gB gene (a gene homologous to herpes simplex virus gB gene) promoter is used as a promoter for expression of an exogenous gene.
    Type: Grant
    Filed: January 30, 1997
    Date of Patent: January 11, 2000
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Kengo Sonoda, Masashi Sakaguchi, Kazuo Matsuo, Fukusaburo Hamada